Patents Assigned to Centre Leon Berard
-
Patent number: 11801400Abstract: A therapy apparatus for treating tissue by emission of focused ultrasound waves, including: a creation surface of a pressure field of focused ultrasound waves divided into at least N sectors having segments of asymmetrical concave curve with centres of curvature; centres of curvature asymmetrical to the extent where the centres of curvature are situated at different distances from the plane of symmetry or from at least one of the axis of symmetry and at different depths taken according to the axis of symmetry; the individual axes intersecting between the focal zones and the creation surface or beyond the focal zones such that the beams originating from the sectors intersect to create a focal coverage zone which is off-axis relative to the plane of symmetry or to the axis of symmetry; the sectors of this creation surface creating energy deposit zones with profiles corresponding to the focal coverage zones.Type: GrantFiled: April 1, 2021Date of Patent: October 31, 2023Assignees: EDAP TMS FRANCE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDECALE (INSERM), UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE LEON BERARDInventors: Marine Sanchez, David Melo De Lima, Jérémy Vincenot
-
Publication number: 20230278983Abstract: The present invention relates to indole derivatives of formula (I?) as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.Type: ApplicationFiled: July 6, 2021Publication date: September 7, 2023Applicants: Universite Claude Bernard Lyon 1, Institut National de la Sante et de la Recherche Madicale, Centre National de la Recherche Scientifique, Ecole Normale Superieure de Lyon, Commissariat à l'Energie Atomique et aux Energies AlternativesS, Centre Leon BerardInventors: Alexandre Bancet, Claude Cochet, Odile Filhol-Cochet, Isabelle Krimm, Thierry Lomberget, Marc Le Borgne
-
Patent number: 11740243Abstract: A non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject is provided. The method comprises the step of measuring the level of ?ig-h3 protein in a blood sample wherein the serum level of ?ig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that ?ig-h3 can be directly detected in the blood sample and ?ig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. Also provided is a ?ig-h3 protein, for use in the treatment of PDAC. The inventors found that ?ig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing ?ig-h3 antibodies in PDAC mouse model reduced tumor growth by enhancing CD8+ T cell anti-tumoral response.Type: GrantFiled: March 15, 2017Date of Patent: August 29, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ CLAUDE BERNARD—LYON, CENTRE LEON BERARD, KIST (KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY)Inventors: Kim In-San, Philippe Bertolino, Ana Hennino
-
Patent number: 11602327Abstract: Method and system for localizing a region of interest in a medium in which cavitation occurs. Method for localizing a region of interest (R) in a medium (M) in which cavitation occurs, the method comprising the steps consisting in: producing cavitation in the region of interest (R), the cavitation generating an acoustic signal, at each of at least three separate positions, detecting a cavitation signal representative of the acoustic signal of the cavitation, for at least two pairs of cavitation signals, determining a delay between the cavitation signals of each pair of cavitation signals, calculating a localization of the region of interest (R) based on the delays and the positions.Type: GrantFiled: August 28, 2017Date of Patent: March 14, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, TOHOKU UNIVERSITYInventors: Cyril Lafon, Jean-Louis Mestas, Maxime Lafond, Shin-Ichiro Umemura
-
Patent number: 11589838Abstract: This method, for determining the local intensity (I0) of an acoustic field propagating in a target region of a soft solid, at a position located within said target region, includes at least the following steps: determining (102) a value of an ultrasound attenuation coefficient (?) of the soft body in the target region; determining (104) a value of the shear modulus (?) of the soft body in the target region; determining (106) a value of the speed of sound (c) in the target region of the soft body; and building (110), with the values determined in steps a), b) and c), a viscoelastic model (M) of a steady-state displacement induced by an acoustic field having a time invariant shape or a viscoelastic model of a difference between two steady-state displacements induced by an acoustic field having a time invariant shape.Type: GrantFiled: March 15, 2019Date of Patent: February 28, 2023Assignees: Institut National de la Sante et la Recherche Medicale (Inserm), Centre Léon-Bérard, Université Claude Bernard Lyon 1Inventors: Kazuhiro Matsui, William Apoutou N'Djin, Rémi Souchon
-
Patent number: 11555191Abstract: An inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus is provided.Type: GrantFiled: August 31, 2018Date of Patent: January 17, 2023Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), HOSPICES CIVILS DE LYON, CENTRE LÉON-BÉRARD, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ CLAUDE BERNARD LYON 1Inventors: Jean Pierre Quivy, Barbara Testoni, Fabien Zoulim, Maelle Locatelli
-
Patent number: 11540806Abstract: This device (2) for generating ultrasonic waves in a target region of a soft solid, includes at least two ultrasound sources (32), light sources (40) distributed around a central axis (X2) of the device (2), for enlightening a zone of the soft solid via subsurface scattering, and a video camera (50), for capturing images of the zone enlightened by the lighting means. The ultrasound source (32), the light sources (40) and the video camera (50) are mounted on a body of the device (20) and oriented toward a common target zone which includes a focal point of the ultrasound sources (32). A boresight of the video camera is aligned on the central axis (X2).Type: GrantFiled: September 29, 2016Date of Patent: January 3, 2023Assignee: Centre Léon-BérardInventors: Jean-Yves Chapelon, Jean-Louis Mestas, Cyril Lafon, Bernard Greillier, René Milleret
-
Publication number: 20220390458Abstract: The invention relates a fluorescent compound of formula I: wherein A is selected from P, P?O and N; ·R1 is a residue comprising an oxygen atom·R2 is a residue comprising an oxygen atom, or a halogen, ·R3, R4 and R5 are alkyls, possibly substituted or a salt or a solvate thereof. The compound is useful as a fluorescent probe sensitive to membrane fluidity and for diagnosing cancer.Type: ApplicationFiled: September 22, 2020Publication date: December 8, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON, CPE LYON FORMATION CONTINUE ET RECHERCHE pouvant être précédée ou suivie par CPE LYON FCR, CENTRE LEON BERARD, HOSPICES CIVILS DE LYONInventors: Thierry GRANJON, Ofelia MANITI, Olivier MARCILLAT, Peter GOEKJIAN, Mouhedine CHENIOUR, Arnaud VIGNERON, David GUEYRARD, Sébastien IBANEZ
-
Publication number: 20220348587Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing the compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.Type: ApplicationFiled: June 3, 2022Publication date: November 3, 2022Applicants: CENTRE LEON BERARD, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Toufic RENNO, Isabelle COSTE-INVERNIZZI, Stéphane GIRAUD, Serge LEBECQUE
-
Patent number: 11384081Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.Type: GrantFiled: September 20, 2017Date of Patent: July 12, 2022Assignees: CENTRE LEON BERARD, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Toufic Renno, Isabelle Coste-Invernizzi, Stéphane Giraud, Serge Lebecque
-
Publication number: 20220186321Abstract: A method of prognosis of patient outcome and of the resistance to a chemotherapy treatment of an individual afflicted by a tumor. The method involves determining the amount of the product of each of at least 21 genes belonging to the group of 160 genes as set forth in SEQ ID NO: 1 to SEQ ID NO: 160.Type: ApplicationFiled: March 27, 2020Publication date: June 16, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE LÉON BERARD, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ CLAUDE BERNARD LYON 1Inventors: Véronique MAGUER-SATTA, Boris GUYOT, Flora CLÉMENT, Pierre SAINTIGNY, Jean-Philippe FOY, Emmanuel DELAY
-
Patent number: 11203641Abstract: The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells.Type: GrantFiled: June 21, 2018Date of Patent: December 21, 2021Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE LEON BERARDInventors: Patrick Mehlen, Agnes Bernet, Julien Fitamant
-
Patent number: 11180556Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: GrantFiled: April 23, 2018Date of Patent: November 23, 2021Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon BerardInventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Publication number: 20210308491Abstract: A therapy apparatus for treating tissue by the emission of focused ultrasound waves, including: a creation surface of a pressure field of focused ultrasound waves divided into at least N sectors having segments of asymmetrical concave curve (S1, S2, . . . ) with centres of curvature; centres of curvature (c1, c2, . . . ) asymmetrical to the extent where the centres of curvature are situated at different distances from the plane of symmetry (A1) or from the axis of symmetry (S) and/or at different depths taken according to the axis of symmetry; the individual axes (a1, a2, . . . ) intersecting between the focal zones (Zc1, Zc2, . . . ) and the creation surface (8) or beyond the focal zones such that the beams originating from the sectors intersect to create a focal coverage zone (Zr) which is off-axis relative to the plane of symmetry (A1) or to the axis of symmetry (S); the sectors of this creation surface (8) creating energy deposit zones with profiles corresponding to the focal coverage zones (Zr).Type: ApplicationFiled: April 1, 2021Publication date: October 7, 2021Applicants: EDAP TMS FRANCE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE LEON BERARDInventors: Marine SANCHEZ, David MELO DE LIMA, Jérémy VINCENOT
-
Patent number: 11130817Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.Type: GrantFiled: October 11, 2016Date of Patent: September 28, 2021Assignees: INNATE PHARMA, CENTRE LÉON BÉRARDInventors: Christophe Caux, Laurent Gauthier, Nicolas Gourdin, Christine Menetrier-Caux, Carine Paturel, Ivan Perrot
-
Publication number: 20210292328Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.Type: ApplicationFiled: September 20, 2017Publication date: September 23, 2021Applicants: CENTRE LEON BERARD, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Toufic RENNO, Isabelle COSTE-INVERNIZZI, Stéphane GIRAUD, Serge LEBECQUE
-
Publication number: 20210177755Abstract: The present invention relates to a pharmaceutical combination product comprising: a liposomal formulation exclusively containing a LPS; and at least one cytotoxic compound. It also relates to its use as an anti-tumour therapy.Type: ApplicationFiled: October 30, 2018Publication date: June 17, 2021Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre Léon BérardInventors: Charles DUMONTET, Abdelkamel CHETTAB
-
Patent number: 10745482Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: GrantFiled: August 6, 2019Date of Patent: August 18, 2020Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Jean Paoli & Irene Calmettes, Universite d' Aix-Marseille, Universite Claude Bernard—Lyon 1, Centre Leon BerardInventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Patent number: 10633446Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: GrantFiled: June 26, 2019Date of Patent: April 28, 2020Assignees: INSERM (Institut National de la Santéet de la Recherche Medicale), Institut Jean Paoli & Irene Calmettes, Universitéd'Aix-Marseille, Universite Claude Bernerd—Lyon }, Centre Leon BerardInventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Patent number: 10533046Abstract: The present disclosure relates to a human CK8 antigen peptide, an antibody, or antibody fragment thereof, or a humanized antibody, specifically binding the peptide having the amino acid sequence of SEQ ID No. 29, a fragment of CK-8. Said molecules can be used use in the detection and/or treatment of tumors whose cells express CK8 protein, in particular the peptide of sequence according to SEQ ID No.29, on their surface.Type: GrantFiled: August 10, 2015Date of Patent: January 14, 2020Assignees: INTERNATIONA—DRUG—DEVELOPMENT—BIOTECH, UNIVERSITE CLAUDE BERNARD LYON 1, HOSPICES CIVILS DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE LEON BERARDInventors: Marie Alexandra Albaret, Jean-Jacques Diaz, Hichem Claude Mertani, Jean-Christophe Saurin, Claudine Vermot-Desroches, Boris Vuillermoz